NCCM
ABUS icon

Nine Chapters Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Nine Chapters Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-73,400
Closed -$1.11M – 945
2014
Q4 		$1.11M Buy
+73,400
New +$1.27M 0.1% 304

Other funds holding ABUS

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Nine Chapters Capital Management's ABUS Position: Q1 2015 in Review

Nine Chapters Capital Management sold out of Arbutus Biopharma (ABUS) in Q1 2015, closing a stake of 73,400 shares — an estimated $1.11M sold.

Nine Chapters Capital Management first reported a position in ABUS in Q4 2014 and held it in 1 quarter. The position peaked at $1.11M in Q4 2014. 77 funds tracked by Wall St. Rank hold ABUS as of Q1 2015.

  • Nine Chapters Capital Management reported no remaining Arbutus Biopharma position as of Q1 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 73,400 Arbutus Biopharma shares in Q1 2015, an estimated $1.11M.
  • Nine Chapters Capital Management first reported a position in Arbutus Biopharma in Q4 2014 and held it in 1 quarter.
  • Nine Chapters Capital Management's Arbutus Biopharma position peaked at $1.11M in Q4 2014.
  • 77 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2015.

Based on Nine Chapters Capital Management's 13F filing for Q1 2015, filed 15 May 2015.